Log In
BCIQ
Print this Print this
 

Dermadexin

  Manage Alerts
Collapse Summary General Information
Company Astion Pharma A/S
DescriptionTopical barrier-repair cream containing proprietary active ingredient pyridine-3-carboxamide glyceryl monocaprylate (P3CGM)
Molecular Target
Mechanism of ActionNF-kappa B (NF-kB) inhibitor; Fatty acid amide hydrolase (FAAH) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationDermatitis
Indication DetailsTreat dermatitis
Regulatory Designation
PartnerCipher Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$32.0M

$4.8M

$27.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/26/2015

$32.0M

$4.8M

$27.2M

Get a free BioCentury trial today